Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus

Clinical Impact of Hemorheology Assessed Using the Microchannel Array Flow Analyzer on Renal Resistive Index in Patients With Type 2 Diabetes Mellitus

“…Small-sized vessels are considered to be present in a portion of skin biopsies along with systemic vessels such as the kidney, heart, and brain. In addition, basic studies have reported that AGEs influence hemorheology by mechanisms such as leukocyte-endothelial interaction and platelet aggregation [28,29]. Thus, the results of this study and that of previous studies may indicate that AGEs and the impairment of hemorheology associated with each other in systemic small-sized vessels consequently lead to an increased systemic vascular resistance, including the kidneys, in patients with type 2 diabetes mellitus.…”

Serotonin Potentiates High-Glucose^|^ndash;Induced Endothelial Injury: the Role of Serotonin and 5-HT2A Receptors in Promoting Thrombosis in Diabetes

“…Previous studies have shown increases in plasma concentration of 5-HT in patients with diabetes (11) and enhanced expression of 5-HT 2 receptors in tissues of diabetic peripheral occlusion model animals (14). 5-HT-induced platelet aggregation is enhanced by advanced glycation endproducts (AGEs), which are involved in the development of microvascular complications (36). It has been suggested that 5-HT is associated with the development of diabetic microvascular complications (37 -39).…”

Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes

“…Such a treatment may be especially effective in the high-risk macrovascular disease group, which includes patients with T2DM. However, few studies have been performed regarding the effects of serotonin 5-HT 2 receptor blockers on macrovascular complications in patients with T2DM [5]. There have been very few studies on the clinical effects of 5-HT 2 receptor blockers compared to aspirin, which is the first line medication for the primary prevention of macrovascular complications [7,8].…”

“…Direct blood exposure to subendothelial collagen due to endothelial damage caused by arteriosclerosis can result in platelet adhesion, platelet aggregation, and serotonin discharge from platelets [5]. Serotonin binds to and activates the 5-HT 2 receptor on the other platelet membranes, resulting in increased platelet aggregation.…”

“…Moreover, serotonin binds with 5-HT 2 receptors on the vascular smooth muscle cell membrane at the inhibitory site to contract vascular smooth muscles. As a result, serotonin inhibits blood flow by increasing the platelet thrombus inside the impaired blood vessels and by contracting the blood vessels from the outside [5,6].…”